[go: up one dir, main page]

EP1009409A1 - Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate - Google Patents

Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate

Info

Publication number
EP1009409A1
EP1009409A1 EP98940536A EP98940536A EP1009409A1 EP 1009409 A1 EP1009409 A1 EP 1009409A1 EP 98940536 A EP98940536 A EP 98940536A EP 98940536 A EP98940536 A EP 98940536A EP 1009409 A1 EP1009409 A1 EP 1009409A1
Authority
EP
European Patent Office
Prior art keywords
dexamethasone
treatment
oil
ester
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98940536A
Other languages
German (de)
English (en)
French (fr)
Inventor
Yossi Bornstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmateam Development Ltd
Original Assignee
Pharmateam Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmateam Development Ltd filed Critical Pharmateam Development Ltd
Publication of EP1009409A1 publication Critical patent/EP1009409A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention provides a novel formulation for the treatment of ocular inflammations and its use.
  • oil-in water type emulsions increase in importance as vehicles for delivery of hydrophobic drugs, for example the fat emulsion described in EP 315079.
  • U.S. Patent 4,340,594 describes a parenterally administered fat emulsion containing a steroid having an anti-inflammatory activity, inter alia dexamethasone palmitate.
  • the fat emulsions described therein are useful in the treatment of rheumatism, immunological hemolytic anemia, idiopathic thrombocytopenic purpura, Paget disease or in conjunction with kidney transplantation.
  • Dexamethasone palmitate works as a prodrug since it is hydro- lyzed in the body by esterases into its bioactive metabolite, dexamethasone. Nonetheless, dexamethasone palmitate has some advantages over conventional water-soluble dexamethasone compositions owing to its lipid content.
  • the present invention is based on the new finding that fat emulsions containing dexamethasone palmitate as the active ingredient are useful in the treatment of ocular inflammations.
  • the present invention relates to a pharmaceutical composition in the form of an oil-in-water emulsion for the treatment of ocular inflammations, comprising, as an active ingredient, an effective amount of a lipophilic ester of dexamethasone, e.g. dexamethasone palmitate.
  • Emulsion is a dispersion of one liquid in a second immiscible liquid. Since the majority of emulsions contain water as one of the phases, it is customary to classify emulsions into two types: the oil-in-water (O/W) type consisting of colloid particles dispersed in water, and the water-in-oil (W/O) type in which the phases are reversed.
  • O/W oil-in-water
  • W/O water-in-oil
  • the continuous liquid is referred as the dispersion medium and the liquid which is in the form of particles is called the disperse phase.
  • each colloid particle has an oily core and an external layer comprising the emulsifiers and the surface active substances.
  • a commercially available fat emulsion which contains 10% soybean oil is Intralipid® (Pharmacia AB, Sweden).
  • Oil-in-water type emulsions which thus comprise oil-based particles dispersed in an aqueous medium, are capable of incorporating into their oily core or into their interfacial film, various hydrophobic drugs, and accordingly have been proposed and used as pharmaceutical carriers of such drugs.
  • the present invention relates to such an oil-in-water type emulsion comprising a lipophilic ester of dexamethasone, as the pharmaceutical active ingredient (namely the drug), for the treatment of ocular inflammations.
  • the emulsion typically comprises, in addition to the active ingredient, an oil component and another component, being an emulsifier and/or a surface active agent.
  • the aqueous phase typically comprises an osmotic pressure regulating agent dissolved therein, for raising the osmotic pressure to physiological levels.
  • concentrations of the ingredients of the emulsion will be given as %, meaning weight of ingredient in hundred volume units of total composition (w/v).
  • the composition of the invention comprises an effective amount of a lipophilic ester of dexamethasone.
  • the term "effective amount” should be understood as an amount sufficient to impart a therapeutic effect.
  • the effective amount in the composition depends on the dosage form, on the therapeutic regime (namely whether the composition is given once daily, twice daily, etc.), the age group of the patient, the severity of the inflammation, as well as on various other factors as known per se. The artisan will have no difficulties in determining, by routine and straight-forward experimentation, as to what constitutes an effective amount in each case.
  • Typical examples of lipophilic esters of dexamethasone are esters of dexamethasone with fatty acids, typically such acids having chains of 6 to about 22 carbon atoms.
  • fatty acid particularly examples are palmitic acid, oleic acid, linoleic acid, stearic acid and others.
  • a particularly preferred fatty acid is palmitic acid (namely the active agent is preferably dexamethasone palmitate).
  • Dexamethasone palmitate may typically be included in the composition ranging between 0.05%, typically 0.1% and preferably 0.15% to 0.5%, typically 0.4% and preferably 0.3%.
  • the oil component is typically a vegetable oil.
  • vegetable oils are oleic acid, linoleic acid, lauric acid, soybean oil, olive oil, sunflower oil, and others.
  • Vegetable oil is typically included in a concentration range of about 5% to 30% (w/v).
  • Typical emulsifiers are phospholipids.
  • phospholipids are phosphatidylcholin, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and sphingomyelins.
  • Phospholipids are preferably included in a concentration range of about 0.5%- 10% (w/v), and particularly in a concentration range of 1-5%.
  • Typical examples of surfactants are polyalkylene glycols having an average molecular weight of 1,000 to 10,000, polyoxyalkylene copolymers having an average molecular weight of 1,000 to 10,000 and poly- oxyethylene fatty acid esters.
  • osmotic pressure regulators examples include sucrose or glycerine.
  • compositions of the inventions may comprise various preservation agents such as methyl, ethyl and butyl paraben, or antioxidants such as ⁇ -tocopherol and ascorbic acid.
  • the pharmaceutical composition of the invention is typically provided in a suitable dosage form, e.g. in the form of eye drops, with the concentration of the active ingredient being such so that a given amount of drops, e.g. 1-2 to be administered at each time.
  • the present invention also provides a method of treatment of ocular inflammations comprising topically applying to the eye an oil-in-water type emulsion, comprising a lipophilic ester of dexamethasone as the active ingredient. Still further provided by the invention is use of a lipophilic ester of dexamethasone and an oil-in-water type emulsion, for the preparation of a topical ocular composition for the treatment of ocular inflammations.
  • Figs. 1-3 are bar graphs (means ⁇ SD) showing the overall score of clinical examination (Fig. 1), the aqueous humor protein content (Fig. 2) and the aqueous humor cell count (Fig. 3) in a variety of treatments: control (A,B), treatment with a reference composition (C,D) and treatment with the inventive composition (E,F).
  • control A,B
  • C,D treatment with a reference composition
  • inventive composition E,F
  • the left eye was injected with LPS (results are shown as columns A, C and E in each of Figs. 1-3) and the right eye was injected with saline (results shown as columns B, D and F in each of Figs. 1-3).
  • the albino rabbit has been selected for this study, since it is widely acclaimed in reports published in the scientific literature, as a most suitable experimental model for the evaluation of newly developed and clinically applied agents for the therapy of anterior uveitis.
  • Rabbits were kept within a limited access laboratory animal facility, at environmental conditions of a target temperature of 17 to 23 °C, a target humidity of 30-70% and a 12-hour light/12-hour dark cycle. Temperature and relative humidity were recorded daily. No deviation from the target values were observed. Rabbits were housed individually in stainless steel cages, mounted in batteries. The cages measured 50x45x48 cm and were fitted with perforated stainless steel floors over undertrays.
  • a complete commercial pelleted rabbit diet (AMBAR 19701) was fed without restriction and the animals were allowed free access to water supplied via a cage-side water bottle.
  • Test composition a commercially available composition comprising an oil-in-water type emulsion containing dexamethasone palmitate at a concentration of 4 mg/ml (LIMETHASONTM, Green Cross Corporation, Japan).
  • Reference composition a commercially available clear aqueous ophthalmic solution, containing 1 mg/ml dexamethasone disodium phosphate (STERODEXTM, Fischer Pharmaceutical Labs. (1975) Ltd., Israel).
  • EIU was carried out in all animals of the three test groups by endotoxin lipopolysaccharide ( PS-E.coli), injected intravitreally at a dose of 2 ⁇ g (40 ⁇ l of 50 ⁇ l LPS/1 ml HPCD [hydroxypropyl cyclodextrin]) into the left eye of each test animal. Throughout the procedure, animals were anesthetized by intramuscular injection of Ketamin HCL 30 mg/kg and Xylazine HCL 5 mg/kg.
  • EIU Control Contralateral (right) eyes served as controls for LPS-injected eyes, and were injected intravitreally in an identical fashion, using 50 ⁇ l of sterile saline.
  • tertiary vessels are considered to be substantially hyperemic.
  • 2 Minimal injection of tertiary vessels and minimal to moderate injection of secondary vessels or iris stroma swelling alone.
  • 3 Moderate injection of secondary and tertiary vessels. .
  • slight swelling of iris stroma (most prominent near the 3:00 and 9:00 o'clock positions).
  • 4 Marked injection of the secondary and tertiary vessels with marked swelling of the iris stroma. Iris appears rugose and may be accompanied by hemorrhage in the anterior chamber.
  • mice were anesthetized (Ketamin HCL 100 mg/kg and Xylazine HCL 15 mg/kg by i.m. injection) and aqueous humor was sampled from both eyes of each test animal, using an appropriate hypodermic needle and syringe. Differential cell counts were determined using a hemocytometer.
  • Table 1 summarizes the data for all test groups, with respect to the evaluation criteria of clinical grading, aqueous humor protein content and cell count, for each of the three types of treatments.
  • FIGs. 1-3 show the same results presented in Table 1 in a more illustrative graphic form: Fig. 1 - overall criterion of clinical examination;
  • Fig. 2 aqueous humor protein content
  • Fig. 3 aqueous humor cell count.
  • A, B - untreated control A - LPS-injected left eye and B - saline-injected right eye.
  • C,D - animals treated with the reference composition C - LPS-injected left eye, D - saline-injected right eye.
  • E.F - animals treated with the test composition E - LPS-injected left eye, F - saline-injected right eye.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98940536A 1997-08-28 1998-08-26 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate Ceased EP1009409A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12164797 1997-08-28
IL12164797A IL121647A (en) 1997-08-28 1997-08-28 Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
PCT/IL1998/000411 WO1999011270A1 (en) 1997-08-28 1998-08-26 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate

Publications (1)

Publication Number Publication Date
EP1009409A1 true EP1009409A1 (en) 2000-06-21

Family

ID=11070569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98940536A Ceased EP1009409A1 (en) 1997-08-28 1998-08-26 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate

Country Status (7)

Country Link
EP (1) EP1009409A1 (zh)
JP (1) JP2001514228A (zh)
CN (1) CN1271288A (zh)
AU (1) AU8883998A (zh)
CA (1) CA2300850A1 (zh)
IL (1) IL121647A (zh)
WO (1) WO1999011270A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295647T3 (es) * 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
DK2319517T3 (da) * 2006-06-01 2013-12-09 Novagali Pharma Sa Anvendelse af prodrugs til okulær, intravenøs administration
KR101541416B1 (ko) 2006-06-01 2015-08-03 산텐 에스에이에스 후안부 질환 치료를 위한 스테로이드 전구약물의 용도
EP2564853B1 (en) * 2007-12-04 2019-02-27 Santen SAS Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
CN108434090A (zh) * 2017-02-14 2018-08-24 高药品股份有限公司 以生理脂肪为基剂的类固醇药膏

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609726B2 (ja) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS62270521A (ja) * 1986-05-16 1987-11-24 Green Cross Corp:The フルルビプロフエン眼投与製剤
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
JPH05124965A (ja) * 1991-11-06 1993-05-21 L T T Kenkyusho:Kk 局所用鼻・気管支疾患治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9911270A1 *

Also Published As

Publication number Publication date
CN1271288A (zh) 2000-10-25
WO1999011270A1 (en) 1999-03-11
AU8883998A (en) 1999-03-22
CA2300850A1 (en) 1999-03-11
IL121647A (en) 2001-07-24
JP2001514228A (ja) 2001-09-11
IL121647A0 (en) 1998-02-08

Similar Documents

Publication Publication Date Title
EP0041772B1 (en) Fat emulsion containing a steroid
RU2048812C1 (ru) Способ лечения воспалительных заболеваний глаза и средство для лечения воспалительных заболеваний глаза
EP1781278B1 (en) Compositions and methods for treating eye disorders and conditions
DE69819751T2 (de) VERWENDUNG VON LÖSLICHEM REZEPTOR FÜR FORTGESCHRITTENE GLYKOSILIERUNG-ENDPRODUKTE (sRAGE) ZUR UNTERDRÜCKUNG DER BESCHLEUNIGTER ATHERIOSKLEROSE
JP2003523925A (ja) 乾燥性眼病の局所治療のためのテトラサイクリンを含む眼科用溶液
US20070265341A1 (en) Compositions and methods for treating eye disorders and conditions
US20210353770A1 (en) Delivery of Urea to Cells of the Macula and Retina Using Liposome Constructs
CN111295169A (zh) 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
EP1009409A1 (en) Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
Hayasaka et al. Ocular changes after intravitreal injection of methanol, formaldehyde, or formate in rabbits
WO1994004155A1 (en) Dehydroepiandrosterone therapy for the treatment of eye disorders
DE69021791T2 (de) Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
JP4475802B2 (ja) 緑内障の局所治療用フルナリジンの使用法
MXPA00001942A (en) Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
Jahn et al. Lipid composition of human aqueous humor
JPH08508975A (ja) 眼科薬送達ビヒクルとしてのサブミクロン乳剤
New et al. Intestinal delivery of calcitonin in pig
Goldstein et al. Dry Eye Disease
ELLIS et al. Comparative intraocular levels of pilocarpine achieved with drops and repository preparations
AU2002309963B2 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
AU2002309963A1 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
Nagata et al. A Mild Progression Type of Naphthalene-Induced Cataract in Brown-Norway Rats.
US20150174122A1 (en) Methods for treating eye disorders using opioid receptor antagonists
HK40009665B (zh) 使用脂質體構建體將尿素遞送至黃斑和視網膜的細胞
van Rooij et al. Oral vitamins C and E as additional treatment in patients with acute anterior uveitis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000322

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/57 A, 7A 61K 9/107 B, 7A 61K 9/00 B, 7A 61P 27/02 B

RTI1 Title (correction)

Free format text: USE OF DEXAMETHASONE PALMITATE FOR THE TREATMENT OF OCULAR INFLAMMATIONS COMPRISING DEXAMETHASONE PALMITATE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20010724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020118